Back to List View Graph View

B7 homolog 3 (B7-H3)

CD276, widely known as B7-H3, is a type I transmembrane glycoprotein and a member of the B7 immune checkpoint ligand superfamily.

Where the papers sit

16 papers from the last 6 months study B7 homolog 3 (B7-H3) directly · updated from PubMed 16 Nov 2026

  • Engineered Cancer Immunotherapy

    Engineered immune therapies are moving toward combinations that improve tumor access, persistence and resistance to immune escape. CAR-T and CAR-NK cells are being paired with checkpoint or B7-H3-directed agents, radiopharmaceutical tumor sensitization and tumor-microenvironment remodeling. TIGIT-CD155 signaling and SPARC-dependent CD276 regulation recur as mechanisms that limit immune-cell function. AI-designed minibinders and comparisons of mRNA with yeast display are broadening how cancer-targeting binders are discovered and optimized.

    6 papers · 37.5%

  • B7-H3 Targeted Therapy

    Antibody-drug conjugates are emerging as the main clinical strategy for B7-H3-positive solid tumors, while CAR-T approaches remain preclinical. YL201 and vobramitamab duocarmazine studies emphasize tumor response alongside cytotoxicity and treatment-related adverse events. Neutrophil-to-lymphocyte ratio and interleukin 6 may help relate baseline inflammation to efficacy and toxicity. Lung cancer dominates, but activity is also being explored in small-cell lung cancer and triple-negative breast cancer.

    5 papers · 31.2%

  • B7-H3 Targeting and Imaging

    B7-H3 targeting is expanding from target validation into tumor imaging, fluorescence-guided surgery and multivalent drug delivery. 68Ga-labeled bicyclic peptides and antibody-fluorophore conjugates aim to improve lesion detection and surgical localization. Colorectal cancer work links B7H3 with EGFR and c-MET co-expression to guide dual-drug conjugates, while CAR-T cells add EGFR engagers for glioblastoma control. Evidence remains largely preclinical, with clinical translation and target heterogeneity still open.

    5 papers · 31.2%

Papers

The 16 papers from the last 6 months that study B7 homolog 3 (B7-H3) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Engineered Cancer Immunotherapy (6)
  1. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  2. Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition. Journal of biochemical and molecular toxicology · 26 Aug 2026 PMID 42647088
  3. AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
  4. Enhancing machine learning-based binder design with high-throughput screening: A comparison of mRNA and yeast display technologies. Protein science : a publication of the Protein Society · 10 Jul 2026 PMID 42429042
  5. GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
  6. A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
B7-H3 Targeted Therapy (5)
  1. Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin 6: Analysis of the Phase I/Ib Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714875
  2. Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
  3. Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer · 23 Jul 2026 PMID 42487497
  4. p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195
  5. "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
B7-H3 Targeting and Imaging (5)
  1. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
  2. B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. Molecular biomedicine · 16 Jun 2026 PMID 42301527
  3. Fluorescence-Guided Surgery of Rhabdomyosarcoma Using a B7-H3 Targeted Antibody-Fluorophore Conjugate. Molecular pharmaceutics · 11 Jun 2026 PMID 42276839
  4. Development and Preclinical Evaluation of 68Ga-Labeled B7-H3-Specific Bicyclic Peptides as Immuno-PET Tracers for Oncology. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263262
  5. B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. Endocrine-related cancer · 2 Jun 2026 PMID 42227355

By study type

Clinical trials (2)
  1. Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin 6: Analysis of the Phase I/Ib Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714875
  2. Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer · 23 Jul 2026 PMID 42487497
Observational studies and case reports (1)
  1. B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. Endocrine-related cancer · 2 Jun 2026 PMID 42227355
Human data, design not indexed (3)
  1. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
  2. Enhancing machine learning-based binder design with high-throughput screening: A comparison of mRNA and yeast display technologies. Protein science : a publication of the Protein Society · 10 Jul 2026 PMID 42429042
  3. "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
Preclinical: animal, cell and lab studies (10)
  1. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  2. Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition. Journal of biochemical and molecular toxicology · 26 Aug 2026 PMID 42647088
  3. AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
  4. Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
  5. GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
  6. A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
  7. B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. Molecular biomedicine · 16 Jun 2026 PMID 42301527
  8. Fluorescence-Guided Surgery of Rhabdomyosarcoma Using a B7-H3 Targeted Antibody-Fluorophore Conjugate. Molecular pharmaceutics · 11 Jun 2026 PMID 42276839
  9. Development and Preclinical Evaluation of 68Ga-Labeled B7-H3-Specific Bicyclic Peptides as Immuno-PET Tracers for Oncology. Journal of medicinal chemistry · 9 Jun 2026 PMID 42263262
  10. p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195